{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.59","upperLimit":"16.11","value":"8.85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"TTR will be summarized descriptively, reporting N, median, mean, standard deviation, standard error (SE), minimum, maximum, and 90% CI for the mean calculated from the SE and asymptotic normal distribution theory.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"MEAN","populationDescription":"Only 2 patients achieved a response.","reportingStatus":"POSTED","timeFrame":"From the start of the treatment until the RECIST measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded, assessed up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months","title":"Time to Recurrence (TTR)","type":"SECONDARY","unitOfMeasure":"months"}